We are international

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
    next      view all

Watch the replay of the "Living Well with Myeloma" Teleconference on CAR T-Cell Therapy
The next “Living Well with Myeloma” teleconference will focus on CAR T-Cell Therapy: What Myeloma Patients & Caregivers Need to Know. It takes place on Thursday, September 22, 2016 at 7 PM ET / 4 PM PT. Speakers are Dr. Rafat Abonour (Indiana University – Simon Cancer Center) and Dr. Edward Stadtmauer (University of Pennsylvania). CAR T cells, or chimeric antigen receptor T cells, are part of a class of cancer therapies known as immunotherapies. With CAR T-cell therapy, a patient’s T cells are harvested and genetically reengineered to become better able to recognize and attack myeloma. The altered T cells are then reinfused into the body with the hope of fighting the disease. To learn about this exciting new therapy, register for free HERE. Pre-registration is highly recommended.

Kayaker Determined to Help his Mother and Uncle Battle Multiple Myeloma Completes 600-Mile Washington to Alaska Trip

Raised More than $20,000 to Support International Myeloma Foundation Research

How Research in Iceland Will Help Myeloma Patients Everywhere
As myeloma researchers at the University of Iceland prepare to launch the exciting iStopMM project, IMF Chairman Dr. Brian Durie examines the benefits this Black Swan Research Initiative® project will generate for the rest of the world: learning, screening, and treating to achieve the best outcomes for myeloma patients everywhere. To read Dr. Durie’s blog, click HERE.

Expanding Our Knowledge About Daratumumab and More
Three important new reports are shedding light on how daratumumab works, reports IMF Chairman Dr. Brian Durie in his blog this week. “Our understanding of its benefits—when used alone and in combinations—is evolving rapidly.” But is treatment outpacing reimbursement? Also, this week, Dr. Durie touches on cancer in 9/11 responders, a study that suggests social status may affect outcomes, and a new bestseller that explores the science-fiction-sounding “microbiome.”

The Most Important Questions Facing Myeloma Experts in 2016

Close to one hundred members of the International Myeloma Working Group (IMWG) gathered in Copenhagen from June 7th to 9th, just prior to the European Hematology Association (EHA) meeting, for the seventh annual IMWG Summit. This important and prestigious meeting allows myeloma experts from around the globe to discuss pressing issues and to set an agenda of publications, clinical trials, and advocacy efforts for the coming year.

Myeloma Experts of the IMWG Tackle Soaring Costs of Care

Recognizing our responsibility to lead the way in addressing costs effectively, members of the International Myeloma Working Group (IMWG), the research arm of the IMF, launched a plan of action at a special session of the June 2016 annual meeting held in Copenhagen this year.

Takeda Receives Marketing Authorization in Canada for NINLARO™ (ixazomib) in Relapsed/Refractory Multiple Myeloma

NINLARO™ is the first and only oral proteasome inhibitor approved to provide a new treatment option for adult patients living with multiple myeloma in Canada who have received at least one prior therapy

NLB New Publications and Resources

Scroll down to learn more.

The IMF’s International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016

 New Categories of Minimal Residual Disease (MRD) Negativity

 Provide Clinical Trial Endpoints and Framework for Cure

Daratumumab (DARZALEX®) Granted Breakthrough Therapy Designation by U.S. FDA for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma
FDA action underscores potential clinical benefit of daratumumab as a backbone therapy in combination with either a proteasome inhibitor (PI) or an immunomodulatory agent for patients who have received at least one prior therapy. Marks the second Breakthrough Therapy Designation for daratumumab

    next      view all